AVTX vs RJF · P/E 0.0, $51.5M cap vs rev $15.91B
Avalo Therapeutics Inc (AVTX) versus RJF (RJF) — a side-by-side from cached financials, not a winner call.
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
RJF (RJF) common stock.
Latest reported AVTX revenue for 2025-09-30 was $0. Net income was -$30.6M. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
Latest reported RJF revenue for 2025-09-30 was $15.91B. Net income was $2.13B. Revenue was up 6.6% from 2024-09-30 to 2025-09-30. RJF currently screens at market cap $0.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. RJF currently screens at market cap $0.
Not investment advice. Open the AVTX and RJF stock pages for the full models.
Not investment advice.